SNDX News and Press, Syndax Pharmaceuticals Inc. From 04/24/24

2024-04-24 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum PR Newswire WALTHAM, Mass. , April 10, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session PR Newswire – Consistent safety and efficacy profiles across adult and pediatric populations – ȁ...

2024-03-28 07:54:58 ET Summary Syndax Pharmaceuticals has two lead molecules in line for FDA review: revumenib for the treatment of acute leukemia and axatilimab for chronic graft-versus-host disease. Syndax is a speculative buy for those willing to take a risk on the FDA approval...

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia PR Newswire – Topline data expected in 4Q24 could support sNDA filing in 1H25 – – Revume...

2024-03-26 17:11:27 ET More on Syndax Pharmaceuticals Syndax Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Syndax Pharmaceuticals, Inc. (SNDX) Q4 2023 Earnings Call Transcript FDA accepts Incyte application for graft-versus-host disease drug ...

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia PR Newswire – PDUFA action date set for September 26, 2024 – – NDA being reviewed under FDA's RTOR program – ...

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer PR Newswire – Steven Closter brings more than 30 years of commercial experience in the biopharmaceutical industry to Syndax – – Company on track for two potential fi...

2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

2024-03-05 04:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...